ALRIB

Current Thesis

Ticker RESOLVED: ALRIB = Riber S.A., French molecular-beam-epitaxy (MBE) tool maker, listed EPA:ALRIB / market cap €272.7M, last €13.00 (2026-04-20). The narrative is live and accelerating — ROSIE (Riber Oxide Silicon Epitaxy) is a 300mm-compatible BTO/silicon-photonics platform targeting AI-datacenter optical interconnects + quantum-computing substrates, 100G+ transceivers, first two units shipped 2025, first US order booked Sep 2025, Japan production order announced Jan 2026. Price has ripped +269.6% vs FTSE Global All Cap over the last 6 months, so we are buying LATE if we buy at all. The bigger problem for US: Riber has NO US ADR and NO OTC pink-sheet. Alpaca paper account (PA3PQALN2DC1) cannot buy EPA:ALRIB. Until a US-tradable sleeve exists, this dossier is a THEME CARD, not a position candidate — use it to identify the US-listed silicon-photonics / compound-semi picks-and-shovels cohort (COHR, LITE, POET, AEHR, IPGP, AAOI) that we can actually route.

Bull Case

• Narrative cohort: ROSIE is the only MBE platform purpose-built for 300mm silicon-photonics BTO modulators — the same physical layer Nvidia/Broadcom/Marvell need for co-packaged optics on Rubin/GB300-class switches. Theme = AI-interconnect bottleneck, squarely in the accelerating band (source: riber.com/product/rosie, semiconductor-today 2026-04-10).
• US demand validation: 2025-09-08 ROSIE order from a US quantum firm (Minalogic / globenewswire); 2026-01 Japan production-line order. Two new-country wins inside 6 months = narrative going international before sell-side models update.
• Operating leverage kicking: 2025 revenue €40.3m (−2.1%) but net income +27% to €5.2m, 13% net margin near record (semiconductor-today 2026-04-10, globenewswire 2026-04-08). Mix shift to higher-margin ROSIE systems is visible in the P&L.
• Backlog tailwind: The Jan-2026 Japan order is NOT in the reported backlog yet — 2026 revenue guidance is "growth vs 2025" BEFORE that upside. Management flagged export-license risk as the only gate.
• Momentum: +269.6% vs FTSE Global All Cap over 6mo (search result 2026-04-20) — tape is confirming the fundamental story, not getting ahead of it.
• Optionality: ROSIE-2 dual-chamber cluster manufactured in 2026, commercial industrialization 2027 → binary step-up in TAM if yields hold.

Bear Case

• NOT TRADABLE FOR US: No ADR (Level 1, 2, or 3), no OTC pink, no ATS. Alpaca rejects Euronext symbols. This single fact dominates — we cannot execute this thesis on our current venue.
• +270% in 6mo is late: By Serenity/DVB rules, a small-cap that has already 3.7x'd is firmly in MATURING → SATURATED transition. Entering here is chasing the last 20-40% of a run, not the first leg. Beginner-trap: peak retail sentiment on a Euronext small cap with €273M cap.
• Tiny float / liquidity: Market cap €272.7M, Paris small-cap liquidity typically <€1M ADV. One institutional unwind prints −15% days. Not a name you can size.
• Revenue concentration: 12 machines shipped in 2025 produced €30.9m of the €40.3m top line — every lumpy quarter swings the stock. H1 2026 revenue print (late July) is the next binary.
• US budget exposure: Services revenue fell 7.8% in 2025 "due notably to budgetary restrictions in the USA" (semiconductor-today 2026-02-03). If NIH/NSF basic-research funding stays compressed into H1 2026, services leg continues to bleed.
• Industrialization is 2027, not 2026: ROSIE commercial scale-up is next-year story. Current multiple is discounting successful ramp before any volume data lands.
• Export-license gate: Management explicitly conditioned 2026 growth guidance on obtaining export licenses. Geopolitical risk (China/Japan) is a live, non-trivial headline risk.

Setup & Price Structure

No US-venue tape exists to analyze. Euronext ALRIB.PA quote (2026-04-20): €13.00, 6mo outperformance +269.6% vs FTSE Global All Cap. Without our Polygon/Finnhub US feed, we have no intraday candles, no 20/50/200-EMA stack, no volume profile, no RSI, no VWAP structure. Assume the tape is extended (RSI>70 likely on weekly) given the magnitude of the rally; assume the 20-EMA sits meaningfully below spot. Do NOT author a setup call blind — the only honest read is: "stock ripped, probably extended, untradable for us either way."

Catalyst Calendar (next 30 days)

• 2026-04-20 → 2026-05-20: no confirmed earnings, no 8-K-equivalent (Euronext uses half-year reporting). Next scheduled print = H1 2026 revenue, typical Riber cadence ~late July 2026 — well outside the 30-day window.
• Potential in-window catalysts (none on a fixed date): incremental ROSIE order announcement (pattern: ~1 per quarter since Sep-2025), export-license milestone on Japan production system, AGM/annual-report mail-out (historical cadence early May).
• Catalyst_date = null for our 30-day window.

What Would Change Our Mind

• Tradability unlock: Riber files a Level-1 ADR OR appears on Alpaca's international-routing menu → re-run dossier end-to-end with real price data and treat as probe-size archetype-2 candidate.
• Pullback to 20-EMA on ALRIB.PA (estimate: €9-10 zone based on magnitude of rally) with narrative intact → the only acceptable re-entry if tradable.
• Christoph routes a US cousin: pivot this dossier into a theme-basket screen (COHR, LITE, POET, AEHR, AAOI, IPGP, ALAB) and rank those on the same silicon-photonics / compound-semi narrative. That's where our edge actually transmits to PnL.
• H1 2026 revenue <€20m (2H-2025 was ~€22m) → thesis broken even on Euronext; narrative/execution divergence.
• ROSIE 2 dual-chamber slips past 2026 → industrialization timeline cracks, multiple de-rates.

Correlation Notes

Theme cousins (tradable on Alpaca, correlate on silicon-photonics / AI-interconnect narrative): COHR (co-packaged optics, MBE customer-adjacent), LITE (datacom transceivers), POET (silicon photonics pure-play), AEHR (burn-in tools for photonics/SiC), AAOI (datacenter optical modules), IPGP (fiber lasers, compound-semi exposure), ALAB (AI interconnect ASICs). Position-sizing rule: if we already hold two names from this cohort, a third same-theme add counts against correlated-cap (20% per 1-cohort limit). Do NOT assume Riber's +270% rips through to any US cousin 1:1 — French small-cap beta is its own animal. Compound-semi capex cycle (OLED, VCSEL, SiC, GaN) is the macro driver; watch AEHR bookings and COHR telecom/datacom split as leading tells for the broader theme.

[operator tag]: Keep ALRIB as DORMANT / theme-card status. Do not synthesize a trade from this dossier on Alpaca. If Christoph clarifies intent ("use this as a theme seed"), spin the cohort screen next cycle.